#8663. Mitochondrial augmentation of CD34+ cells from healthy donors and patients with mitochondrial DNA disorders confers functional benefit

October 2026publication date
Proposal available till 30-05-2025
4 total number of authors per manuscript3000 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Medicine (miscellaneous);
Biomedical Engineering;
Developmental Biology;
Cell Biology;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
900 $800 $700 $600 $
Contract №8663.1 Contract №8663.2 Contract №8663.3 Contract №8663.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

Abstract:
This study discusses mitochondrial augmentation therapy (MAT) as a potential disease-modifying therapy for mtDNA disorders. It is a method of ex vivo augmentation of hematopoietic stem and progenitor cells (HSPCs) with normal exogenous mitochondria. Here, we show that MAT is feasible and dose dependent, and improves mitochondrial content and oxygen consumption of healthy and diseased hematopoietic stem and progenitor cells (HSPCs).
Keywords:
Mitochondria; mtDNA; mitochondrial dysfunction; hematopoietic stem and progenitor cells; oxygen consumption

Contacts :
0